Home › Cystic Fibrosis › NCT07312734

Study to Enable New Diagnostics for Pulmonary Microbes in People With CF

Study to Enable New Diagnostics for Pulmonary Microbes in People With CF (SEND-CF)

Who can join

Ages 16 and older · All sexes

Inclusion Criteria:

* ≥ 16 years of age on day of study visit
* Documentation of CF Diagnosis
* Able to expectorate sputum
* Percent predicted FEV1 ≥ 30%

Exclusion Criteria:

* History of solid organ transplantation
* History of active malignancy (or treatment for malignancy) in 12 months prior to the study visit
* Pregnant

About the study

Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.

Sponsor: Chris Goss · Participants: 300 · Started: Mar 30, 2026

Contact the study team

• Nikita Midamba · Phone: 206-884-0599
• Anna Mead · Phone: 206-884-7531

Official record on ClinicalTrials.gov — NCT07312734

Locations in the U.S.

Conditions

• Cystic Fibrosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.